floxuridine has been researched along with Neoplasms in 177 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ten patients were studied, 7 receiving streptozotocin and floxuridine for neuroendocrine tumours and three receiving cisplatinum for non-neuroendocrine neoplasms." | 3.68 | Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine. ( Buchanan, KD; Cunningham, RT; Irvine, GB; Johnston, CF; McIlrath, EM; McNeill, A, 1990) |
| "Capecitabine (Cape) is a prodrug that is metabolized into 5'-deoxy-5-fluorocytidine (DFCR), 5'-deoxy-5-fluorouridine (DFUR), and 5-fluorouracil (5-FU) after oral administration." | 2.80 | Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ( Chen, X; Dai, X; Deng, P; Ding, L; Ji, C; Zhong, D, 2015) |
| "Among 15 colorectal cancer patients (10 with prior irinotecan), the calculated median progression-free survival was 5." | 2.74 | Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. ( Batist, G; Chi, KN; Chia, SK; Gelmon, KA; Janoff, AS; Louie, AC; Mayer, LD; Miller, WH; Swenson, CE, 2009) |
| " Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine." | 2.73 | A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. ( Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008) |
| "Six Japanese cancer patients treated with gemcitabine plus cisplatin were examined." | 2.71 | Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ( Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T, 2005) |
| "Forty patients and 75 pharmacokinetic time-courses were available for analysis." | 2.71 | Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ( Lokiec, F; Rezaí, K; Urien, S, 2005) |
| "Gemcitabine alone was given in cycle 1 as a 24-h, 2-h or 1-h i." | 2.71 | A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. ( Chen, A; Grem, JL; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Rowedder, A; Takimoto, CH; Xu, Y, 2003) |
| " Plasma concentration data were pooled and analyzed using a population pharmacokinetic program (NONMEM)." | 2.71 | Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study. ( Delaloge, S; Di Palma, M; Forgue, ST; Le Chevalier, T; Llombart, A; Ni, L; Tourani, JM; Turpin, F, 2004) |
| " hydroxyurea (HU) in combination with i." | 2.70 | Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ( Garcia, AA; Jeffers, S; Koda, RT; Muggia, FM; Pujari, M; Silberman, H; Spears, CP, 2001) |
| "As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| " Although the MTD was not reached, it can be stated that the dosage administered in this study could be explored in a larger trial." | 2.67 | A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease. ( Antimi, M; Majoli, L; Minelli, M; Pandolfi, A; Papa, G; Stampino, CG, 1993) |
| " Pharmacokinetic parameters showed very wide interpatient variability." | 2.67 | Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. ( Creaven, PJ; Frank, C; Levine, EG; Meropol, NJ; Petrelli, NJ; Proefrock, A; Raghavan, D; Rodriguez-Bigas, M; Rustum, YM; Udvary-Nagy, S, 1994) |
| "Thus, loss of the S-phase checkpoint in cancer cells may provide the molecular basis for selective killing of tumors compared with normal tissues." | 2.42 | The mechanism of action of radiosensitization of conventional chemotherapeutic agents. ( Blackstock, AW; Lawrence, TS; McGinn, C, 2003) |
| "To address its potential in cancer treatment, we will also discuss the regulatory mechanisms of UPase gene expression and its induction in tumor tissues." | 2.42 | Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. ( Cao, D; Pizzorno, G, 2004) |
| "Floxuridine oligomers are anticancer oligonucleotide drugs composed of a number of floxuridine residues." | 1.62 | Floxuridine Oligomers Activated under Hypoxic Environment. ( Ishinabe, T; Morihiro, K; Okamoto, A; Osawa, T; Osumi, H; Takatsu, M, 2021) |
| " The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (dFCR), 5'-deoxy-5-fluorouridine (dFUR), 5-FU, and fluoro-β-alanine (FBAL) using data from a heterogeneous population of cancer patients (n = 237) who participated in seven clinical studies." | 1.51 | Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. ( Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM, 2019) |
| "To evaluate the cancer-targeting ability of rhamnose moiety, the rhamnose-conjugated fluorescence dye rhodamine B (Rha-RhB) was constructed." | 1.51 | Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy. ( Jin, L; Li, Y; Liu, X; Lu, L; Qu, J; Xiao, M; Xu, L; Yin, Z, 2019) |
| "Floxuridine is a very effective drug with high potency in the treatment of various tumors but its utility is limited by its low efficiency of cellular uptake." | 1.48 | Lipophilic Prodrug of Floxuridine Loaded into Solid Lipid Nanoparticles: ( Barge, A; Battaglia, L; Chirio, D; Dianzani, C; Ferrara, B; Gallarate, M; Giordano, S; Peira, E; Sapino, S, 2018) |
| "Since both FdU and BdM can kill cancer cells, the FdU-BdM twin drug nanoparticles can overcome the multidrug resistance (MDR) of tumor cells and present an excellent anticancer activity." | 1.42 | Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy. ( Huang, P; Shi, L; Su, Y; Yan, D; Zhang, T; Zhou, L; Zhu, X, 2015) |
| " The high bioavailability (~90%) following oral dosing with RFUdR indicates that this DAMM prodrug may be suitable for oral dosing to deliver FUdR and RA for cancer chemotherapy." | 1.39 | Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice. ( Knaus, EE; Wiebe, LI; Xia, Z, 2013) |
| "The aim of this study was to evaluate the association of gemcitabine pathway SNPs with detailed pharmacokinetic measures obtained from solid tumor patients receiving gemcitabine-based therapy." | 1.38 | Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. ( Dudek, AZ; Greeno, EW; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Mitra, AK; Skubitz, KM, 2012) |
| "250 Japanese cancer patients who received 30-minute intravenous infusions of gemcitabine at 800 or 1000 mg/m2 in the period between September 2002 and July 2004 were recruited for this study." | 1.36 | Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. ( Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T, 2010) |
| "Whether anticancer drug combinations act synergistically or antagonistically often depends on the ratio of the agents being combined." | 1.34 | Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. ( Harasym, NL; Harasym, TO; Harvie, P; Johnstone, SA; Mayer, LD; Tardi, PG, 2007) |
| " Fixing synergistic drug ratios in pharmaceutical carriers provides an avenue by which anticancer drug combinations can be optimized prospectively for maximum therapeutic activity during preclinical development and differs from current practice in which dosing regimens are developed empirically in late-stage clinical trials based on tolerability." | 1.33 | Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. ( Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG, 2006) |
| "In the flanks of FVB/N female mice, 4 tumors per animal were established by subcutaneous injection of 1 x 10(5) cells of NG4TL4 sarcoma cells, HSV1-tk-transduced NG4TL4-STK cells, or a mixture of these cells in different proportions to model different efficacies of transfection and HSV1-tk gene expression levels in tumors." | 1.33 | Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. ( Deng, WP; Gelovani, JG; Hwang, JJ; Lin, M; Liu, RS; Wang, HE; Wei, HJ; Yu, HM, 2006) |
| "The sensitivity of cancer cells to capecitabine, which is an oral, tumor-selective pre-prodrug of 5-fluorouracil may correlate better to the TP/DPD ratio than to levels of either enzyme alone." | 1.33 | Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry. ( Bacsó, Z; Eliason, JF; Megyeri, A; Shields, A, 2005) |
| "In cultures of human cancer cell lines, the highest level of cytotoxicity was shown by 5-FU itself, followed by 5'-dFUrd." | 1.30 | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. ( Ishikawa, T; Ishitsuka, H; Miwa, M; Mori, K; Nishida, M; Sawada, N; Shimma, N; Umeda, I; Ura, M, 1998) |
| " The mean elimination half-life of intravenous dFUrd increased with the dose from 15 to 22 min." | 1.30 | Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. ( De Bruijn, EA; Highley, MS; Maes, RA; Reeuwijk, HJ; Tjaden, UR; Van Der Heyden, SA; Van Oosterom, AT; Van Slooten, H, 1999) |
| "Most tumors are resistant to therapy by thymidylate synthase (TS) inhibitors due to their high levels of TS." | 1.30 | Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues. ( Collins, JM; Katki, AG; Klecker, RW, 1999) |
| "Since cancer is mainly a disease of older persons, the incidence of malignancies of all types is expected to increase during the coming decades." | 1.29 | [Chemotherapy for older cancer patients]. ( Urushizaki, I, 1993) |
| "Our findings suggest that chromosomal abnormalities in childhood malignancies cannot generally be explained by the presence of FdU- or FdU plus caffeine-induced fragile sites." | 1.28 | Relationship between chemical-induced fragile sites and chromosomal breakpoints in malignant cells in children. ( Crist, WM; Douglass, EC; Lewis, S; Raimondi, SC; Ribeiro, RC; Valentine, M; Williams, DL, 1992) |
| "Doxifluridine (5'-dFUR) is a prodrug of 5 fluorouracil (5-FU) synthesized in an attempt to improve the therapeutic index compared with 5-FU." | 1.28 | A phase I study of doxifluridine as a five-day stepped-dose continuous infusion. ( Bishop, JF; Guentert, TW; Hillcoat, BL; Morris, RG; Olver, IN; Reece, PA, 1990) |
| " With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor." | 1.27 | 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. ( Armstrong, RD; Cadman, E, 1983) |
| "Floxuridine (5-FUDR) was administered by continuous venous infusion using an ambulatory portable pump in a phase I study designed to establish the optimal (maximal) daily dose rate to deliver a minimum of 14 days of drug therapy." | 1.27 | Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy. ( Lokich, JJ; Paul, S; Sonneborn, H; Zipoli, T, 1983) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| " The optimal dosage for a phase II study was suggested to be less than 2,100 mg/body/day." | 1.27 | [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Furue, H; Kanamaru, R; Kimura, K; Komita, T; Murakami, M; Nakao, I; Ohta, K; Saito, T; Wakui, A; Yokoyama, M, 1985) |
| "The response rate of gastric cancer was 14." | 1.27 | [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985) |
| " Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index." | 1.27 | Phase II clinical evaluation of doxifluridine. ( Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986) |
| " This diarrhea, however, disappeared rapidly by decreasing the dosage or termination of treatment." | 1.27 | [A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Tsukagoshi, S, 1987) |
| "Thrombocytopenia was less frequently encountered." | 1.26 | Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. ( Abele, R; Alberto, P; Bollag, W; Germano, G; Heintz, R; Seematter, RJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 96 (54.24) | 18.7374 |
| 1990's | 32 (18.08) | 18.2507 |
| 2000's | 19 (10.73) | 29.6817 |
| 2010's | 25 (14.12) | 24.3611 |
| 2020's | 5 (2.82) | 2.80 |
| Authors | Studies |
|---|---|
| Vine, KL | 1 |
| Locke, JM | 1 |
| Bremner, JB | 1 |
| Pyne, SG | 1 |
| Ranson, M | 1 |
| Park, SM | 1 |
| Yang, H | 1 |
| Park, SK | 1 |
| Kim, HM | 1 |
| Kim, BH | 2 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Lewandowska, M | 1 |
| Ruszkowski, P | 3 |
| Chojnacka, K | 1 |
| Kleczewska, N | 1 |
| Hoffmann, M | 1 |
| Kacprzak, K | 1 |
| Celewicz, L | 1 |
| Liu, J | 1 |
| Si, S | 1 |
| Xu, J | 1 |
| Xue, P | 1 |
| Li, K | 1 |
| Wang, WX | 1 |
| Jiang, WL | 1 |
| Mao, GJ | 1 |
| Tan, ZK | 1 |
| Tan, M | 1 |
| Li, CY | 1 |
| Zhu, L | 1 |
| Yang, J | 1 |
| Ma, Y | 2 |
| Zhu, X | 3 |
| Zhang, C | 2 |
| Xu, L | 1 |
| Liu, X | 2 |
| Yin, Z | 1 |
| Jin, L | 1 |
| Lu, L | 1 |
| Qu, J | 1 |
| Xiao, M | 1 |
| Jacobs, BAW | 1 |
| Deenen, MJ | 1 |
| Joerger, M | 1 |
| Rosing, H | 1 |
| de Vries, N | 1 |
| Meulendijks, D | 1 |
| Cats, A | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| Huitema, ADR | 1 |
| Sato, A | 1 |
| Hiramoto, A | 1 |
| Kim, HS | 1 |
| Wataya, Y | 1 |
| Morihiro, K | 1 |
| Ishinabe, T | 1 |
| Takatsu, M | 1 |
| Osumi, H | 1 |
| Osawa, T | 1 |
| Okamoto, A | 1 |
| Gao, C | 1 |
| Liang, X | 1 |
| Mo, S | 1 |
| Zhang, N | 1 |
| Sun, D | 1 |
| Dai, Z | 1 |
| Chirio, D | 1 |
| Peira, E | 1 |
| Battaglia, L | 1 |
| Ferrara, B | 1 |
| Barge, A | 1 |
| Sapino, S | 1 |
| Giordano, S | 1 |
| Dianzani, C | 1 |
| Gallarate, M | 1 |
| Jin, C | 1 |
| Zhang, H | 1 |
| Zou, J | 1 |
| Liu, Y | 1 |
| Li, F | 1 |
| Wang, R | 2 |
| Xuan, W | 1 |
| Ye, M | 1 |
| Tan, W | 1 |
| Wang, H | 1 |
| Zhao, Y | 1 |
| Zhang, Z | 1 |
| Mou, Q | 1 |
| Ding, F | 1 |
| Gao, X | 1 |
| Yan, D | 2 |
| He, S | 1 |
| Xie, C | 1 |
| Jiang, Y | 1 |
| Pu, K | 1 |
| Baraniak, D | 2 |
| Baranowski, D | 2 |
| Framski, G | 1 |
| Boryski, J | 2 |
| Xia, Z | 1 |
| Knaus, EE | 1 |
| Wiebe, LI | 1 |
| Deng, P | 1 |
| Ji, C | 1 |
| Dai, X | 1 |
| Zhong, D | 1 |
| Ding, L | 1 |
| Chen, X | 1 |
| Zhang, T | 1 |
| Huang, P | 1 |
| Shi, L | 1 |
| Su, Y | 1 |
| Yan, Y | 1 |
| Han, X | 1 |
| Qing, Y | 1 |
| Condie, AG | 1 |
| Gorityala, S | 1 |
| Yang, S | 1 |
| Xu, Y | 2 |
| Zhang, Y | 1 |
| Gerson, SL | 1 |
| Batist, G | 1 |
| Gelmon, KA | 1 |
| Chi, KN | 1 |
| Miller, WH | 1 |
| Chia, SK | 1 |
| Mayer, LD | 3 |
| Swenson, CE | 1 |
| Janoff, AS | 2 |
| Louie, AC | 1 |
| Bowen, C | 1 |
| Wang, S | 1 |
| Licea-Perez, H | 1 |
| Kong, X | 1 |
| Fan, H | 1 |
| Liang, J | 1 |
| Gupta, N | 1 |
| Chen, Y | 1 |
| Fang, F | 1 |
| Chang, Y | 1 |
| Viertl, D | 1 |
| Bischof Delaloye, A | 1 |
| Lanz, B | 1 |
| Poitry-Yamate, C | 1 |
| Gruetter, R | 1 |
| Mlynarik, V | 1 |
| Ametamey, SM | 1 |
| Ross, TL | 1 |
| Lehr, HA | 1 |
| André, PA | 1 |
| Perillo-Adamer, F | 1 |
| Kosinski, M | 1 |
| Dupertuis, YM | 1 |
| Buchegger, F | 1 |
| Sugiyama, E | 2 |
| Kaniwa, N | 2 |
| Kim, SR | 2 |
| Hasegawa, R | 2 |
| Saito, Y | 2 |
| Ueno, H | 2 |
| Okusaka, T | 2 |
| Ikeda, M | 2 |
| Morizane, C | 1 |
| Kondo, S | 1 |
| Yamamoto, N | 2 |
| Tamura, T | 1 |
| Furuse, J | 2 |
| Ishii, H | 2 |
| Yoshida, T | 2 |
| Saijo, N | 2 |
| Sawada, J | 2 |
| Tsume, Y | 1 |
| Hilfinger, JM | 1 |
| Amidon, GL | 1 |
| Yi, JW | 1 |
| Barry, NP | 1 |
| Furrer, MA | 1 |
| Zava, O | 1 |
| Dyson, PJ | 1 |
| Therrien, B | 1 |
| Kislukhin, G | 1 |
| Murphy, ML | 1 |
| Jafari, M | 1 |
| Long, AD | 1 |
| Mitra, AK | 1 |
| Kirstein, MN | 1 |
| Khatri, A | 1 |
| Skubitz, KM | 1 |
| Dudek, AZ | 1 |
| Greeno, EW | 1 |
| Kratzke, RA | 1 |
| Lamba, JK | 1 |
| Yasuno, H | 1 |
| Kurasawa, M | 1 |
| Yanagisawa, M | 1 |
| Sato, Y | 1 |
| Harada, N | 1 |
| Mori, K | 3 |
| Lawrence, TS | 1 |
| Blackstock, AW | 1 |
| McGinn, C | 1 |
| Grem, JL | 2 |
| Quinn, MG | 1 |
| Keith, B | 1 |
| Monahan, BP | 1 |
| Hamilton, JM | 1 |
| Harold, N | 1 |
| Nguyen, D | 1 |
| Takimoto, CH | 1 |
| Rowedder, A | 1 |
| Pang, J | 1 |
| Morrison, G | 1 |
| Chen, A | 1 |
| HIGGINS, GA | 1 |
| WHERRY, DC | 1 |
| BAGSHAW, MA | 2 |
| BIRNIE, GD | 1 |
| HEIDELBERGER, C | 7 |
| ANSFIELD, FJ | 5 |
| WELCH, AD | 1 |
| ETALA, E | 1 |
| SOFIA, V | 1 |
| ROMERO, LM | 1 |
| CLIFTON, KH | 1 |
| SZYBALSKI, W | 1 |
| GOLLIN, FF | 1 |
| VERMUND, H | 1 |
| OETTGEN, HF | 2 |
| CLIFFORD, P | 2 |
| CANDLER, P | 1 |
| WATKINS, E | 2 |
| SULLIVAN, RD | 3 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| SHEININ, R | 1 |
| BROCKMAN, RW | 1 |
| ANDERSON, EP | 1 |
| MILLER, E | 1 |
| MARUYAMA, Y | 1 |
| SILINI, G | 1 |
| KAPLAN, HS | 1 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| WATNE, AL | 2 |
| JOHNSON, RO | 1 |
| CASTRO, R | 1 |
| MOERTEL, CG | 1 |
| REITEMEIER, RJ | 1 |
| BOLTON, CF | 1 |
| SHORTER, RG | 1 |
| WOLBERG, WH | 3 |
| ROGERS, LS | 1 |
| LOVE, R | 1 |
| RABSON, AS | 1 |
| WILDY, P | 1 |
| LAWTON, RL | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| WILSON, WL | 2 |
| DELAGARZA, JG | 1 |
| RAPP, F | 1 |
| BUTEL, JS | 1 |
| FELDMAN, LA | 1 |
| KITAHARA, T | 1 |
| MELNICK, JL | 1 |
| FISCHER, GA | 1 |
| VONESSEN, CF | 1 |
| GRIESBACH, L | 1 |
| GHOBAR, A | 1 |
| RICH, MA | 1 |
| PEREZ, AG | 1 |
| EIDINOFF, ML | 1 |
| Choi, TH | 1 |
| Ahn, SH | 1 |
| Kwon, HC | 1 |
| Choi, CW | 1 |
| Awh, OD | 1 |
| Lim, SM | 1 |
| Delaloge, S | 1 |
| Llombart, A | 1 |
| Di Palma, M | 1 |
| Tourani, JM | 1 |
| Turpin, F | 1 |
| Ni, L | 1 |
| Forgue, ST | 1 |
| Le Chevalier, T | 1 |
| Cao, D | 1 |
| Pizzorno, G | 1 |
| Lin, NM | 1 |
| Zeng, S | 1 |
| Ma, SL | 1 |
| Fan, Y | 1 |
| Zhong, HJ | 1 |
| Fang, L | 1 |
| Noordhuis, P | 1 |
| Holwerda, U | 1 |
| Van Laar, JA | 1 |
| Van der Wilt, CL | 2 |
| Peters, GJ | 1 |
| Megyeri, A | 1 |
| Bacsó, Z | 1 |
| Shields, A | 1 |
| Eliason, JF | 1 |
| Yonemori, K | 1 |
| Kikura-Hanajiri, R | 1 |
| Ozawa, S | 1 |
| Urien, S | 1 |
| Rezaí, K | 1 |
| Lokiec, F | 1 |
| Wang, HE | 1 |
| Yu, HM | 1 |
| Liu, RS | 1 |
| Lin, M | 1 |
| Gelovani, JG | 1 |
| Hwang, JJ | 1 |
| Wei, HJ | 1 |
| Deng, WP | 1 |
| Harasym, TO | 2 |
| Tardi, PG | 2 |
| Harasym, NL | 2 |
| Shew, CR | 1 |
| Johnstone, SA | 2 |
| Ramsay, EC | 1 |
| Bally, MB | 1 |
| Pandyra, AA | 1 |
| Berg, R | 1 |
| Vincent, M | 1 |
| Koropatnick, J | 1 |
| Harvie, P | 1 |
| Camidge, DR | 1 |
| Gail Eckhardt, S | 1 |
| Gore, L | 1 |
| O'Bryant, CL | 1 |
| Leong, S | 1 |
| Basche, M | 1 |
| Holden, SN | 1 |
| Musib, L | 1 |
| Baldwin, J | 1 |
| Darstein, C | 1 |
| Thornton, D | 1 |
| Finn, RS | 1 |
| Britten, CD | 1 |
| Caradonna, SJ | 1 |
| Cheng, YC | 1 |
| Gelijkens, CF | 2 |
| De Leenheer, AP | 2 |
| Abele, R | 1 |
| Alberto, P | 2 |
| Seematter, RJ | 1 |
| Germano, G | 1 |
| Heintz, R | 1 |
| Bollag, W | 1 |
| Frei, E | 1 |
| Garnick, MB | 1 |
| Ensminger, WD | 1 |
| Israel, M | 1 |
| Steele, GD | 1 |
| Kaplan, WD | 1 |
| Come, SE | 1 |
| Armstrong, RD | 2 |
| Cadman, E | 2 |
| Kono, A | 1 |
| Hara, Y | 2 |
| Sugata, S | 1 |
| Karube, Y | 1 |
| Matsushima, Y | 1 |
| Ishitsuka, H | 4 |
| Gesmonde, J | 1 |
| Wu, T | 1 |
| Kimura, K | 3 |
| Suga, S | 1 |
| Lokich, JJ | 1 |
| Sonneborn, H | 1 |
| Paul, S | 1 |
| Zipoli, T | 1 |
| Buchwald, H | 2 |
| Yunis, JJ | 1 |
| Soreng, AL | 1 |
| Rohde, TD | 1 |
| Hill, DL | 1 |
| Montgomery, JA | 1 |
| Sandra, P | 1 |
| Lévi, F | 2 |
| Bjarnason, GA | 1 |
| Hrushesky, WJ | 5 |
| Urushizaki, I | 2 |
| Creaven, PJ | 1 |
| Rustum, YM | 1 |
| Petrelli, NJ | 1 |
| Meropol, NJ | 1 |
| Raghavan, D | 1 |
| Rodriguez-Bigas, M | 1 |
| Levine, EG | 1 |
| Frank, C | 1 |
| Udvary-Nagy, S | 1 |
| Proefrock, A | 1 |
| Antimi, M | 1 |
| Majoli, L | 1 |
| Minelli, M | 1 |
| Stampino, CG | 1 |
| Pandolfi, A | 1 |
| Papa, G | 1 |
| Vokes, EE | 2 |
| O'Brien, SM | 1 |
| Vogelzang, NJ | 2 |
| Schilsky, RL | 2 |
| Ratain, MJ | 2 |
| Garufi, C | 1 |
| Giunta, S | 1 |
| Aschelter, A | 1 |
| Pace, R | 1 |
| Nisticò, C | 1 |
| Terzoli, E | 1 |
| Diasio, RB | 1 |
| Lu, Z | 1 |
| Zhang, R | 1 |
| Shahinian, HS | 1 |
| Jansen, WJ | 1 |
| Pinedo, HM | 1 |
| Feller, N | 1 |
| Bamberger, U | 1 |
| Boven, E | 1 |
| Zambonin, CG | 1 |
| Palmisano, F | 1 |
| Nishida, M | 2 |
| Hino, A | 1 |
| Matsumoto, T | 1 |
| Yoshikubo, T | 1 |
| Paillard, F | 1 |
| Denning, C | 1 |
| Pitts, JD | 1 |
| Miwa, M | 2 |
| Ura, M | 1 |
| Sawada, N | 1 |
| Ishikawa, T | 1 |
| Shimma, N | 1 |
| Umeda, I | 1 |
| González Barón, M | 1 |
| Van Der Heyden, SA | 1 |
| Highley, MS | 1 |
| De Bruijn, EA | 1 |
| Tjaden, UR | 1 |
| Reeuwijk, HJ | 1 |
| Van Slooten, H | 1 |
| Van Oosterom, AT | 1 |
| Maes, RA | 1 |
| Collins, JM | 2 |
| Klecker, RW | 2 |
| Katki, AG | 1 |
| Garcia, AA | 1 |
| Muggia, FM | 3 |
| Spears, CP | 1 |
| Jeffers, S | 2 |
| Silberman, H | 1 |
| Pujari, M | 1 |
| Koda, RT | 1 |
| Chabner, BA | 2 |
| Myers, CE | 1 |
| Coleman, CN | 1 |
| Johns, DG | 1 |
| Rozencweig, M | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
| Danenberg, PV | 1 |
| Cummings, FJ | 1 |
| Hoovis, ML | 1 |
| Calabresi, P | 3 |
| Smellie, SG | 1 |
| Parsons, PG | 1 |
| Oberfield, RA | 2 |
| Ribeiro, RC | 1 |
| Douglass, EC | 1 |
| Williams, DL | 1 |
| Raimondi, SC | 1 |
| Valentine, M | 1 |
| Lewis, S | 1 |
| Crist, WM | 1 |
| Kamata, R | 1 |
| Saito, T | 3 |
| Yamashita, T | 1 |
| Sekiguchi, K | 1 |
| Shibuya, H | 1 |
| Horiuchi, J | 1 |
| Ebata, K | 1 |
| Sanuki, E | 1 |
| Endo, M | 1 |
| Sato, K | 1 |
| Levin, RD | 1 |
| Gordon, JH | 1 |
| Simonich, W | 1 |
| Mellijor, A | 1 |
| Sanchez, R | 1 |
| Williams, RM | 1 |
| Raschko, JW | 1 |
| Warfield, EE | 1 |
| Doroshow, JH | 1 |
| Chan, KK | 1 |
| Russell, C | 1 |
| Colombo, N | 1 |
| Speyer, JL | 1 |
| Sehgal, K | 1 |
| Sorich, J | 1 |
| Leichman, L | 1 |
| Beller, U | 1 |
| Chu, E | 1 |
| Johnson, P | 1 |
| Yeh, GC | 1 |
| Allegra, CJ | 1 |
| Reece, PA | 2 |
| Olver, IN | 2 |
| Morris, RG | 2 |
| Bishop, JF | 2 |
| Guentert, TW | 2 |
| Hill, HS | 1 |
| Hillcoat, BL | 2 |
| Bertino, JR | 1 |
| Romanini, A | 1 |
| Lanning, RM | 1 |
| Cunningham, RT | 1 |
| Johnston, CF | 1 |
| Irvine, GB | 1 |
| McIlrath, EM | 1 |
| McNeill, A | 1 |
| Buchanan, KD | 1 |
| Anderson, N | 3 |
| Lokich, J | 3 |
| Bern, M | 3 |
| Wallach, S | 3 |
| Moore, C | 3 |
| Williams, D | 3 |
| Umprayn, V | 1 |
| Morgan, RG | 1 |
| Winkelmann, JJ | 1 |
| Paschoud, N | 1 |
| Peytremann, R | 1 |
| Bruyere, A | 1 |
| Righetti, A | 1 |
| Decoster, G | 1 |
| Holdener, EE | 1 |
| Tuchman, M | 1 |
| Roemeling, RV | 1 |
| Hrushesky, WA | 1 |
| Sothern, RB | 1 |
| O'Dea, RF | 1 |
| Nakao, I | 2 |
| Wakui, A | 1 |
| Yokoyama, M | 1 |
| Kanamaru, R | 1 |
| Furue, H | 1 |
| Komita, T | 1 |
| Ohta, K | 2 |
| Murakami, M | 1 |
| Niitani, H | 1 |
| Abe, O | 1 |
| Yoshida, Y | 1 |
| Kimura, T | 1 |
| Kurihara, M | 1 |
| Taguchi, T | 1 |
| Sakai, K | 1 |
| Terasawa, T | 1 |
| Irie, K | 1 |
| Okajima, K | 1 |
| Yamamoto, M | 1 |
| Kawahara, T | 1 |
| Satomi, T | 1 |
| Tomita, K | 1 |
| Yamaguchi, A | 1 |
| Okumura, T | 1 |
| Hinshaw, KA | 1 |
| Bouwman, DL | 1 |
| Weaver, DW | 1 |
| Kinzie, J | 1 |
| Lönn, U | 1 |
| Lönn, S | 1 |
| Hurteloup, P | 1 |
| Armand, JP | 1 |
| Cappelaere, P | 1 |
| Metz, R | 1 |
| Kerbrat, P | 1 |
| Keiling, R | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Schraub, S | 1 |
| Bastit, P | 1 |
| Herrmann, R | 1 |
| Nishimura, J | 1 |
| Kamiyama, T | 1 |
| Tsukagoshi, S | 1 |
| Speth, PA | 1 |
| Kinsella, TJ | 1 |
| Belanger, K | 1 |
| Smith, R | 1 |
| Rowland, JB | 1 |
| Saneyoshi, M | 1 |
| Umprain, V | 1 |
| Greenwald, ES | 1 |
| Goffinet, DR | 1 |
| Liebman, IM | 1 |
| Maguire, HC | 1 |
| Nervi, C | 1 |
| Casale, C | 1 |
| Cortese, M | 1 |
| Caspersson, T | 1 |
| Farber, S | 1 |
| Foley, GE | 1 |
| Killander, D | 1 |
| Zetterberg, A | 1 |
| Blomgren, SE | 1 |
| Kisken, WA | 1 |
| Casida, JE | 1 |
| Engel, JL | 1 |
| Nishizawa, Y | 1 |
| Rege, VB | 1 |
| Albala, MM | 1 |
| Leone, LA | 1 |
| Bisel, HF | 1 |
| Krementz, ET | 1 |
| Lien, RC | 1 |
| Prohaska, JV | 1 |
| Dendy, PP | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Giovanella, BC | 1 |
| Lohman, WA | 1 |
| Windheuser, JJ | 1 |
| Jato, J | 1 |
| DeConti, RC | 1 |
| Kaplan, SR | 1 |
| Papac, RJ | 1 |
| Oldham, RK | 1 |
| Siwarski, D | 1 |
| McCoy, JL | 1 |
| Plata, EJ | 1 |
| Herberman, RB | 1 |
| Cady, B | 1 |
| Booth, JC | 1 |
| Ove, R | 1 |
| Kenis, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
24 reviews available for floxuridine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Anticancer Strategy Targeting Cell Death Regulators: Switching the Mechanism of Anticancer Floxuridine-Induced Cell Death from Necrosis to Apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Floxuridine; Gene Expression Regulation, Neopla | 2020 |
Anticancer Strategy Targeting Cell Death Regulators: Switching the Mechanism of Anticancer Floxuridine-Induced Cell Death from Necrosis to Apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Floxuridine; Gene Expression Regulation, Neopla | 2020 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabin | 2003 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabin | 2003 |
BIOCHEMICAL MECHANISMS OF ACTION OF FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Ligases; Neoplasms; Pharmacology; Pyrimidines; Resear | 1963 |
BIOCHEMICAL MECHANISMS OF ACTION OF FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Ligases; Neoplasms; Pharmacology; Pyrimidines; Resear | 1963 |
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me | 1963 |
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me | 1963 |
[CHEMOTHERAPY BY PERFUSION FOR CANCER OF THE STOMACH AND COLON].
Topics: Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Cyclophosphamide; Flox | 1963 |
[CHEMOTHERAPY BY PERFUSION FOR CANCER OF THE STOMACH AND COLON].
Topics: Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Cyclophosphamide; Flox | 1963 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation.
Topics: Animals; Antimetabolites, Antineoplastic; Floxuridine; Fluorouracil; Gene Expression Regulation, Enz | 2004 |
Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation.
Topics: Animals; Antimetabolites, Antineoplastic; Floxuridine; Fluorouracil; Gene Expression Regulation, Enz | 2004 |
Implantable infusion pumps.
Topics: Animals; Antineoplastic Agents; Drug Implants; Feedback; Female; Floxuridine; Glucose; Heparin; Huma | 1984 |
Implantable infusion pumps.
Topics: Animals; Antineoplastic Agents; Drug Implants; Feedback; Female; Floxuridine; Glucose; Heparin; Huma | 1984 |
Selective uptake and retention of anticancer agents by sensitive cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Floxuridine; Fluorouracil; Humans; Melphala | 1980 |
Selective uptake and retention of anticancer agents by sensitive cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Floxuridine; Fluorouracil; Humans; Melphala | 1980 |
Clinical cancer chronotherapy trials: a review.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Circadian Rhythm; Clinical Trials as Topic; Drug | 1995 |
Clinical cancer chronotherapy trials: a review.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Circadian Rhythm; Clinical Trials as Topic; Drug | 1995 |
Cancer chronotherapy: is there a right time in the day to treat?
Topics: Animals; Antineoplastic Agents; Circadian Rhythm; Floxuridine; Fluorouracil; Humans; Neoplasms; Neop | 1995 |
Cancer chronotherapy: is there a right time in the day to treat?
Topics: Animals; Antineoplastic Agents; Circadian Rhythm; Floxuridine; Fluorouracil; Humans; Neoplasms; Neop | 1995 |
Fluoropyrimidine catabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluoroura | 1995 |
Fluoropyrimidine catabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluoroura | 1995 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
Thymidylate synthetase - a target enzyme in cancer chemotherapy.
Topics: Animals; Binding, Competitive; Cysteine; Deoxyuracil Nucleotides; DNA, Neoplasm; Female; Floxuridine | 1977 |
Thymidylate synthetase - a target enzyme in cancer chemotherapy.
Topics: Animals; Binding, Competitive; Cysteine; Deoxyuracil Nucleotides; DNA, Neoplasm; Female; Floxuridine | 1977 |
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F | 1991 |
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F | 1991 |
Antimetabolites.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cytarabine; Cytidine; Drug Interactions; Drug Resis | 1991 |
Antimetabolites.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cytarabine; Cytidine; Drug Interactions; Drug Resis | 1991 |
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.
Topics: Circadian Rhythm; DNA; Floxuridine; Fluorouracil; Humans; Neoplasms | 1990 |
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.
Topics: Circadian Rhythm; DNA; Floxuridine; Fluorouracil; Humans; Neoplasms | 1990 |
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorodeoxyuri | 1989 |
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorodeoxyuri | 1989 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Solid tumor chemotherapy: What have we to offer.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Floxuridine; Fluorouracil; Huma | 1970 |
Solid tumor chemotherapy: What have we to offer.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Floxuridine; Fluorouracil; Huma | 1970 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
18 trials available for floxuridine and Neoplasms
| Article | Year |
|---|---|
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; | 2015 |
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; | 2015 |
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Re | 2009 |
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Re | 2009 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dr | 2003 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dr | 2003 |
Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Midd | 2004 |
Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Midd | 2004 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cis | 2005 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cis | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2008 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2008 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1994 |
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1994 |
A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Humans; Interferon | 1993 |
A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Humans; Interferon | 1993 |
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Drug Administration Schedule; Female; Floxuridine | 1993 |
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Drug Administration Schedule; Female; Floxuridine | 1993 |
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom | 1995 |
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom | 1995 |
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2001 |
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2001 |
[Multi-institutional trials of radiation and Furtulon combination therapy for malignant tumors].
Topics: Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule | 1992 |
[Multi-institutional trials of radiation and Furtulon combination therapy for malignant tumors].
Topics: Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule | 1992 |
Phase I clinical trial with floxuridine and high-dose continuous infusion of leucovorin calcium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Floxuridine; H | 1991 |
Phase I clinical trial with floxuridine and high-dose continuous infusion of leucovorin calcium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Floxuridine; H | 1991 |
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Topics: Aged; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Female; Floxurid | 1991 |
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Topics: Aged; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Female; Floxurid | 1991 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
[Clinical trial of 5'-DFUR against various malignant tumors].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Adm | 1985 |
[Clinical trial of 5'-DFUR against various malignant tumors].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Adm | 1985 |
135 other studies available for floxuridine and Neoplasms
| Article | Year |
|---|---|
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
Topics: Cell Line, Tumor; Humans; Neoplasms; Plasminogen Activator Inhibitor 2; Uridine; Urokinase-Type Plas | 2010 |
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
Topics: Cell Line, Tumor; Humans; Neoplasms; Plasminogen Activator Inhibitor 2; Uridine; Urokinase-Type Plas | 2010 |
Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxyuridine; Drug Design; Fluorine; Humans; Neoplasms; Tri | 2010 |
Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxyuridine; Drug Design; Fluorine; Humans; Neoplasms; Tri | 2010 |
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
Topics: Amides; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxy | 2016 |
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
Topics: Amides; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxy | 2016 |
Construction of synergistic pH/H
Topics: A549 Cells; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; | 2022 |
Construction of synergistic pH/H
Topics: A549 Cells; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; | 2022 |
A novel near-infrared theranostic probe for accurate cancer chemotherapy
Topics: Animals; Antineoplastic Agents; Boronic Acids; Cell Line, Tumor; Coumarins; Floxuridine; Fluorescent | 2021 |
A novel near-infrared theranostic probe for accurate cancer chemotherapy
Topics: Animals; Antineoplastic Agents; Boronic Acids; Cell Line, Tumor; Coumarins; Floxuridine; Fluorescent | 2021 |
Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Cell Line, Tumor; Clofarabine; Drug | 2022 |
Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Cell Line, Tumor; Clofarabine; Drug | 2022 |
Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy.
Topics: Alternaria; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytarabine; Floxuridine; Glycosi | 2019 |
Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy.
Topics: Alternaria; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytarabine; Floxuridine; Glycosi | 2019 |
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2019 |
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2019 |
Floxuridine Oligomers Activated under Hypoxic Environment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Floxuridine; Humans; Hypoxia; Mice, Inbr | 2021 |
Floxuridine Oligomers Activated under Hypoxic Environment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Floxuridine; Humans; Hypoxia; Mice, Inbr | 2021 |
Near-Infrared Cyanine-Loaded Liposome-like Nanocapsules of Camptothecin-Floxuridine Conjugate for Enhanced Chemophotothermal Combination Cancer Therapy.
Topics: Camptothecin; Floxuridine; Humans; Liposomes; Nanocapsules; Neoplasms | 2018 |
Near-Infrared Cyanine-Loaded Liposome-like Nanocapsules of Camptothecin-Floxuridine Conjugate for Enhanced Chemophotothermal Combination Cancer Therapy.
Topics: Camptothecin; Floxuridine; Humans; Liposomes; Nanocapsules; Neoplasms | 2018 |
Lipophilic Prodrug of Floxuridine Loaded into Solid Lipid Nanoparticles:
Topics: Cell Line; Cell Line, Tumor; Drug Carriers; Floxuridine; Humans; Lipids; Nanoparticles; Neoplasms; P | 2018 |
Lipophilic Prodrug of Floxuridine Loaded into Solid Lipid Nanoparticles:
Topics: Cell Line; Cell Line, Tumor; Drug Carriers; Floxuridine; Humans; Lipids; Nanoparticles; Neoplasms; P | 2018 |
Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Delivery Systems; Floxuridine; Hydrophobic and Hydrop | 2018 |
Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Delivery Systems; Floxuridine; Hydrophobic and Hydrop | 2018 |
Age-dependent effects of floxuridine (FUdR) on senescent pathology and mortality in the nematode Caenorhabditis elegans.
Topics: Age Factors; Animals; Antimetabolites, Antineoplastic; Caenorhabditis elegans; Disease Models, Anima | 2019 |
Age-dependent effects of floxuridine (FUdR) on senescent pathology and mortality in the nematode Caenorhabditis elegans.
Topics: Age Factors; Animals; Antimetabolites, Antineoplastic; Caenorhabditis elegans; Disease Models, Anima | 2019 |
Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides To Reverse Chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA; Down-Regulation; Drug Carriers; Drug Resistan | 2019 |
Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides To Reverse Chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA; Down-Regulation; Drug Carriers; Drug Resistan | 2019 |
An Organic Afterglow Protheranostic Nanoassembly.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dimerization; Drug Delivery Systems; Floxuridine; | 2019 |
An Organic Afterglow Protheranostic Nanoassembly.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dimerization; Drug Delivery Systems; Floxuridine; | 2019 |
Nucleoside dimers analogs containing floxuridine and thymidine with unnatural linker groups: synthesis and cancer line studies. Part III.
Topics: Antineoplastic Agents; Cell Survival; Click Chemistry; Cycloaddition Reaction; Dimerization; Floxuri | 2019 |
Nucleoside dimers analogs containing floxuridine and thymidine with unnatural linker groups: synthesis and cancer line studies. Part III.
Topics: Antineoplastic Agents; Cell Survival; Click Chemistry; Cycloaddition Reaction; Dimerization; Floxuri | 2019 |
Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Floxuridine; Kidney; Liver; Lung; Mice; Mi | 2013 |
Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Floxuridine; Kidney; Liver; Lung; Mice; Mi | 2013 |
Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Cell Line, Tumor; Drug Carriers; Drug Delivery Sy | 2015 |
Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Cell Line, Tumor; Drug Carriers; Drug Delivery Sy | 2015 |
3'-O- and 5'-O-Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Floxuridine; Humans; Molecular Conformation; Neopla | 2016 |
3'-O- and 5'-O-Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Floxuridine; Humans; Molecular Conformation; Neopla | 2016 |
Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; DNA Replicat | 2016 |
Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; DNA Replicat | 2016 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neop | 2009 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neop | 2009 |
Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5'-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA Primers; E | 2009 |
Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5'-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA Primers; E | 2009 |
Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Flow Cytometry; Floxu | 2011 |
Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Flow Cytometry; Floxu | 2011 |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Computer Simulation; Cytidine Deaminase; | 2010 |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Computer Simulation; Cytidine Deaminase; | 2010 |
Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.
Topics: Amino Acids; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Dipeptides; Drug Del | 2011 |
Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.
Topics: Amino Acids; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Dipeptides; Drug Del | 2011 |
Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages.
Topics: Antineoplastic Agents; Floxuridine; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Solubility; | 2012 |
Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages.
Topics: Antineoplastic Agents; Floxuridine; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Solubility; | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug | 2012 |
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase | 2012 |
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase | 2012 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxyc | 2013 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxyc | 2013 |
5-Fluorodeoxyuridine (adenocarcinoma, small bowel).
Topics: Adenocarcinoma; Antineoplastic Agents; Floxuridine; Humans; Intestine, Small; Intestines; Neoplasms | 1961 |
5-Fluorodeoxyuridine (adenocarcinoma, small bowel).
Topics: Adenocarcinoma; Antineoplastic Agents; Floxuridine; Humans; Intestine, Small; Intestines; Neoplasms | 1961 |
Approaches for combined radiation and chemotherapy.
Topics: Antineoplastic Agents; DNA; DNA, Bacterial; DNA, Neoplasm; Floxuridine; Humans; Methotrexate; Neopla | 1963 |
Approaches for combined radiation and chemotherapy.
Topics: Antineoplastic Agents; DNA; DNA, Bacterial; DNA, Neoplasm; Floxuridine; Humans; Methotrexate; Neopla | 1963 |
In vitro synthesis of acidsoluble thymine compounds by human neoplastic tissues.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Neoplasms; Thymine | 1963 |
In vitro synthesis of acidsoluble thymine compounds by human neoplastic tissues.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Neoplasms; Thymine | 1963 |
Chemotherapy of disseminated solid tumors.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Humans; Neoplasms | 1962 |
Chemotherapy of disseminated solid tumors.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Humans; Neoplasms | 1962 |
SUMMARY OF INFORMAL DISCUSSIONS ON THE ROLE OF PYRIMIDINE ANTAGONISTS FOLLOWING PAPERS BY DR. PRUSOFF AND DR. CALABRESI.
Topics: Antimetabolites; Antineoplastic Agents; Floxuridine; Fluorouracil; Idoxuridine; Neoplasms; Nucleosid | 1963 |
SUMMARY OF INFORMAL DISCUSSIONS ON THE ROLE OF PYRIMIDINE ANTAGONISTS FOLLOWING PAPERS BY DR. PRUSOFF AND DR. CALABRESI.
Topics: Antimetabolites; Antineoplastic Agents; Floxuridine; Fluorouracil; Idoxuridine; Neoplasms; Nucleosid | 1963 |
INCORPORATION OF I-125-LABELED IODODEOXYURIDINE INTO THE DEOXYRIBONUCLEIC ACID OF MURINE AND HUMAN TISSUES FOLLOWING THERAPEUTIC DOSES.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Floxuridine; Geriatrics; Idoxuridine; Intestine, Small; | 1963 |
INCORPORATION OF I-125-LABELED IODODEOXYURIDINE INTO THE DEOXYRIBONUCLEIC ACID OF MURINE AND HUMAN TISSUES FOLLOWING THERAPEUTIC DOSES.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Floxuridine; Geriatrics; Idoxuridine; Intestine, Small; | 1963 |
CONTINUOUS INTRA-ARTERIAL OR INTRAVENOUS INFUSION OF 5-FLUORO-2-DEOXYURIDINE: THERAPEUTIC AND TOXIC EFFECTS.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Chemotherapy, Cancer, Regiona | 1963 |
CONTINUOUS INTRA-ARTERIAL OR INTRAVENOUS INFUSION OF 5-FLUORO-2-DEOXYURIDINE: THERAPEUTIC AND TOXIC EFFECTS.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Chemotherapy, Cancer, Regiona | 1963 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
STUDIES ON THE EFFECT OF 5-FLUORO-2'-DEOXYURIDINE ON POLYAMA T FORMATION IN MOUSE EMBRYO CELLS.
Topics: Animals; Antigens; Deoxyuridine; DNA; DNA, Viral; Electrons; Embryo, Mammalian; Embryo, Nonmammalian | 1964 |
STUDIES ON THE EFFECT OF 5-FLUORO-2'-DEOXYURIDINE ON POLYAMA T FORMATION IN MOUSE EMBRYO CELLS.
Topics: Animals; Antigens; Deoxyuridine; DNA; DNA, Viral; Electrons; Embryo, Mammalian; Embryo, Nonmammalian | 1964 |
THE ADMINISTRATION OF CHEMO-THERAPEUTIC AGENTS IN THE TREATMENT OF ADVANCED HEAD AND NECK CANCER.
Topics: Alkylating Agents; Antineoplastic Agents; Aorta; Aorta, Abdominal; Black People; Catheterization; Et | 1964 |
THE ADMINISTRATION OF CHEMO-THERAPEUTIC AGENTS IN THE TREATMENT OF ADVANCED HEAD AND NECK CANCER.
Topics: Alkylating Agents; Antineoplastic Agents; Aorta; Aorta, Abdominal; Black People; Catheterization; Et | 1964 |
RATIONALE FOR THE DESIGN OF FLUORINATED PYRIMIDINES.
Topics: Animals; Antimetabolites; DNA; Floxuridine; Fluorouracil; Halogenation; Ligases; Mice; Neoplasms; Ne | 1964 |
RATIONALE FOR THE DESIGN OF FLUORINATED PYRIMIDINES.
Topics: Animals; Antimetabolites; DNA; Floxuridine; Fluorouracil; Halogenation; Ligases; Mice; Neoplasms; Ne | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
PROTRACTED ARTERIAL INFUSION CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Catheterization; Colonic Neop | 1964 |
PROTRACTED ARTERIAL INFUSION CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Catheterization; Colonic Neop | 1964 |
STUDIES OF THE LSA ASCITES LYMPHOMA OF C57B1 MICE. II. RADIOSENSITIZATION IN VIVO WITH 5-BROMODEOXYCYTIDINE AND COMBINED 5-FLUORODEOXYURIDINE AND 5-BROMODEOXYCYTIDINE.
Topics: Ascites; Bromodeoxycytidine; DNA; DNA, Neoplasm; Floxuridine; Lymphoma; Mice; Neoplasms; Neoplasms, | 1963 |
STUDIES OF THE LSA ASCITES LYMPHOMA OF C57B1 MICE. II. RADIOSENSITIZATION IN VIVO WITH 5-BROMODEOXYCYTIDINE AND COMBINED 5-FLUORODEOXYURIDINE AND 5-BROMODEOXYCYTIDINE.
Topics: Ascites; Bromodeoxycytidine; DNA; DNA, Neoplasm; Floxuridine; Lymphoma; Mice; Neoplasms; Neoplasms, | 1963 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
[REGIONAL CHEMOTHERAPY OF MALIGNANT TUMORS. I. PROLONGED INTRA-ARTERIAL INFUSION OF ANTIMETABOLITES].
Topics: Antimetabolites; Catheterization; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Injections | 1964 |
[REGIONAL CHEMOTHERAPY OF MALIGNANT TUMORS. I. PROLONGED INTRA-ARTERIAL INFUSION OF ANTIMETABOLITES].
Topics: Antimetabolites; Catheterization; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Injections | 1964 |
CEREBELLAR ATAXIA ASSOCIATED WITH FLUORINATED PYRIMIDINE THERAPY.
Topics: Ataxia; Cerebellar Ataxia; Cerebellar Diseases; Floxuridine; Fluorouracil; Gastrointestinal Neoplasm | 1964 |
CEREBELLAR ATAXIA ASSOCIATED WITH FLUORINATED PYRIMIDINE THERAPY.
Topics: Ataxia; Cerebellar Ataxia; Cerebellar Diseases; Floxuridine; Fluorouracil; Gastrointestinal Neoplasm | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
STUDIES ON THE MECHANISM OF HUMAN TUMOR RESISTANCE TO THE FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorine; Metabolism; Neoplasms; Nucleosides; Pharmacology; Pyrimid | 1964 |
STUDIES ON THE MECHANISM OF HUMAN TUMOR RESISTANCE TO THE FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorine; Metabolism; Neoplasms; Nucleosides; Pharmacology; Pyrimid | 1964 |
CANCER CHEMOTHERAPY BY CONTINUOUS INTRA-ARTERIAL INFUSION. EXPERIENCE OF THE VETERANS ADMINISTRATION SURGICAL ADJUVANT CANCER CHEMOTHERAPY INFUSION STUDY GROUP.
Topics: Floxuridine; Geriatrics; Hemiplegia; Hemorrhage; Infusions, Intra-Arterial; Infusions, Parenteral; L | 1964 |
CANCER CHEMOTHERAPY BY CONTINUOUS INTRA-ARTERIAL INFUSION. EXPERIENCE OF THE VETERANS ADMINISTRATION SURGICAL ADJUVANT CANCER CHEMOTHERAPY INFUSION STUDY GROUP.
Topics: Floxuridine; Geriatrics; Hemiplegia; Hemorrhage; Infusions, Intra-Arterial; Infusions, Parenteral; L | 1964 |
CHANGES IN THE NUCLEOLUS OF NORMAL AND NEOPLASTIC CELLS INFECTED WITH RIBOVIRUSES AND DEOXYRIBOVIRUSES.
Topics: Cell Nucleolus; Cell Nucleus; Colchicine; Floxuridine; Herpesviridae; Neoplasms; Neoplasms, Experime | 1964 |
CHANGES IN THE NUCLEOLUS OF NORMAL AND NEOPLASTIC CELLS INFECTED WITH RIBOVIRUSES AND DEOXYRIBOVIRUSES.
Topics: Cell Nucleolus; Cell Nucleus; Colchicine; Floxuridine; Herpesviridae; Neoplasms; Neoplasms, Experime | 1964 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
THE COMPARISON OF RADIATION AND ANTIMETABOLITE RESPONSES OF GENETICALLY ALTERED MURINE LEUKEMIC CELLS.
Topics: Animals; Antimetabolites; Chromosomes; Floxuridine; Genetics; Idoxuridine; Leukemia; Leukemia, Exper | 1965 |
THE COMPARISON OF RADIATION AND ANTIMETABOLITE RESPONSES OF GENETICALLY ALTERED MURINE LEUKEMIC CELLS.
Topics: Animals; Antimetabolites; Chromosomes; Floxuridine; Genetics; Idoxuridine; Leukemia; Leukemia, Exper | 1965 |
The potentiation by 5-iodo-2'-deoxyuridine (IUDR) of the tumor-inhibitory activity of 5-fluoro-2'-deoxyuridine (FUDR).
Topics: Antineoplastic Agents; Deoxyuridine; Floxuridine; Humans; Idoxuridine; Neoplasms; Nucleosides; Nucle | 1960 |
The potentiation by 5-iodo-2'-deoxyuridine (IUDR) of the tumor-inhibitory activity of 5-fluoro-2'-deoxyuridine (FUDR).
Topics: Antineoplastic Agents; Deoxyuridine; Floxuridine; Humans; Idoxuridine; Neoplasms; Nucleosides; Nucle | 1960 |
Effect of 5-fluorodeoxyuridine on the proliferation of Rous sarcoma virus.
Topics: Floxuridine; Neoplasms; Nucleosides; Nucleotides; Rous sarcoma virus; Sarcoma; Viruses | 1962 |
Effect of 5-fluorodeoxyuridine on the proliferation of Rous sarcoma virus.
Topics: Floxuridine; Neoplasms; Nucleosides; Nucleotides; Rous sarcoma virus; Sarcoma; Viruses | 1962 |
In vivo comparison of IVDU and IVFRU in HSV1-TK gene expressing tumor bearing rats.
Topics: Animals; Cell Line, Tumor; Drug Monitoring; Drug Stability; Floxuridine; Genetic Therapy; Herpesviru | 2004 |
In vivo comparison of IVDU and IVFRU in HSV1-TK gene expressing tumor bearing rats.
Topics: Animals; Cell Line, Tumor; Drug Monitoring; Drug Stability; Floxuridine; Genetic Therapy; Herpesviru | 2004 |
Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidi | 2004 |
Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidi | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Dihyd | 2005 |
Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Dihyd | 2005 |
Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Female; Floxuridine; Fluorodeox | 2006 |
Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Female; Floxuridine; Fluorodeox | 2006 |
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; | 2006 |
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; | 2006 |
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridine; G1 Phase; Humans; Neoplasms; Proto-Onc | 2007 |
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridine; G1 Phase; Humans; Neoplasms; Proto-Onc | 2007 |
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Dose-Response | 2007 |
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Dose-Response | 2007 |
The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells.
Topics: Cells, Cultured; Cytosol; DNA Glycosylases; DNA Polymerase II; DNA-Directed DNA Polymerase; DNA, Neo | 1980 |
The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells.
Topics: Cells, Cultured; Cytosol; DNA Glycosylases; DNA Polymerase II; DNA-Directed DNA Polymerase; DNA, Neo | 1980 |
Gas chromatographic measurement of urinary 5-fluoro-2'-deoxyuridine levels after barium salt precipitation and sephadex LH-20 cleanup.
Topics: Barium; Chemical Precipitation; Chromatography; Chromatography, Gas; Dextrans; Floxuridine; Humans; | 1980 |
Gas chromatographic measurement of urinary 5-fluoro-2'-deoxyuridine levels after barium salt precipitation and sephadex LH-20 cleanup.
Topics: Barium; Chemical Precipitation; Chromatography; Chromatography, Gas; Dextrans; Floxuridine; Humans; | 1980 |
Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; | 1982 |
Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; | 1982 |
Biochemical pharmacology in medical oncology.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Floxuridine; Fluorouracil; Humans; Infusions, Intra-A | 1981 |
Biochemical pharmacology in medical oncology.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Floxuridine; Fluorouracil; Humans; Infusions, Intra-A | 1981 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
Topics: Animals; Biotransformation; Floxuridine; Guinea Pigs; Humans; Male; Mice; Middle Aged; Neoplasms; Pe | 1983 |
Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
Topics: Animals; Biotransformation; Floxuridine; Guinea Pigs; Humans; Male; Mice; Middle Aged; Neoplasms; Pe | 1983 |
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female; | 1983 |
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female; | 1983 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy.
Topics: Drug Evaluation; Floxuridine; Humans; Infusions, Parenteral; Neoplasms | 1983 |
Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy.
Topics: Drug Evaluation; Floxuridine; Humans; Infusions, Parenteral; Neoplasms | 1983 |
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Drug Administration Schedule; Drug Ev | 1984 |
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Drug Administration Schedule; Drug Ev | 1984 |
[Phase II study of FF-705 by Clinical Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Drug Administratio | 1984 |
[Phase II study of FF-705 by Clinical Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Drug Administratio | 1984 |
Current overview of implantable infusion devices.
Topics: Female; Floxuridine; Heparin; Humans; Infusions, Intra-Arterial; Insulin Infusion Systems; Liver Neo | 1983 |
Current overview of implantable infusion devices.
Topics: Female; Floxuridine; Heparin; Humans; Infusions, Intra-Arterial; Insulin Infusion Systems; Liver Neo | 1983 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
Constitutive fragile sites and cancer.
Topics: Adolescent; Adult; Animals; Caffeine; Cells, Cultured; Child; Chromosome Fragile Sites; Chromosome F | 1984 |
Constitutive fragile sites and cancer.
Topics: Adolescent; Adult; Animals; Caffeine; Cells, Cultured; Child; Chromosome Fragile Sites; Chromosome F | 1984 |
Measurement of 5-fluoro-2'-deoxyuridine serum levels by gas chromatography chemical ionization mass spectrometry.
Topics: Floxuridine; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms | 1980 |
Measurement of 5-fluoro-2'-deoxyuridine serum levels by gas chromatography chemical ionization mass spectrometry.
Topics: Floxuridine; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms | 1980 |
[Chemotherapy for older cancer patients].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
[Chemotherapy for older cancer patients].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; | 1995 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; | 1995 |
Gas chromatography-mass spectrometry identification of a novel N3-methylated metabolite of 5'-deoxy-5-fluorouridine in plasma of cancer patients undergoing chemotherapy.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Floxuridine; Gas Chromatography-Mass Sp | 1996 |
Gas chromatography-mass spectrometry identification of a novel N3-methylated metabolite of 5'-deoxy-5-fluorouridine in plasma of cancer patients undergoing chemotherapy.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Floxuridine; Gas Chromatography-Mass Sp | 1996 |
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Topics: Animals; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Floxuridine; Fluorouracil; Human | 1996 |
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Topics: Animals; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Floxuridine; Fluorouracil; Human | 1996 |
Bystander effects in enzyme/prodrug gene therapy.
Topics: Antineoplastic Agents; Floxuridine; Ganciclovir; Gap Junctions; Genetic Therapy; Genetic Vectors; He | 1997 |
Bystander effects in enzyme/prodrug gene therapy.
Topics: Antineoplastic Agents; Floxuridine; Ganciclovir; Gap Junctions; Genetic Therapy; Genetic Vectors; He | 1997 |
Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes.
Topics: Animals; Apoptosis; Cell Communication; Cell Line; Cricetinae; Drug Synergism; Floxuridine; Ganciclo | 1997 |
Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes.
Topics: Animals; Apoptosis; Cell Communication; Cell Line; Cricetinae; Drug Synergism; Floxuridine; Ganciclo | 1997 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Female; Floxuridi | 1999 |
Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Female; Floxuridi | 1999 |
Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues.
Topics: Animals; Arabinofuranosyluracil; Cell Division; DNA; Floxuridine; Fluorine Radioisotopes; Humans; Me | 1999 |
Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues.
Topics: Animals; Arabinofuranosyluracil; Cell Division; DNA; Floxuridine; Fluorine Radioisotopes; Humans; Me | 1999 |
Overview of early and investigational chemotherapeutic agents in solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Com | 1976 |
Overview of early and investigational chemotherapeutic agents in solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Com | 1976 |
Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cytarabine; Drug Administration Schedule; Drug Evaluation | 1979 |
Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cytarabine; Drug Administration Schedule; Drug Evaluation | 1979 |
Effects of thymidine analogues on murine and human cells.
Topics: Animals; Bromodeoxyuridine; Cell Count; Cell Line; Deoxyuridine; Fibroblasts; Floxuridine; Humans; I | 1979 |
Effects of thymidine analogues on murine and human cells.
Topics: Animals; Bromodeoxyuridine; Cell Count; Cell Line; Deoxyuridine; Fibroblasts; Floxuridine; Humans; I | 1979 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Relationship between chemical-induced fragile sites and chromosomal breakpoints in malignant cells in children.
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Chromosome Aberrations; Chromosome Fragile Sit | 1992 |
Relationship between chemical-induced fragile sites and chromosomal breakpoints in malignant cells in children.
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Chromosome Aberrations; Chromosome Fragile Sit | 1992 |
Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.
Topics: Ascitic Fluid; Dose-Response Relationship, Drug; Drug Evaluation; Floxuridine; Humans; Injections, I | 1991 |
Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.
Topics: Ascitic Fluid; Dose-Response Relationship, Drug; Drug Evaluation; Floxuridine; Humans; Injections, I | 1991 |
Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; | 1990 |
Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; | 1990 |
A phase I study of doxifluridine as a five-day stepped-dose continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Evaluatio | 1990 |
A phase I study of doxifluridine as a five-day stepped-dose continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Evaluatio | 1990 |
Modulation of fluoropyrimidines by pretreatment with antifolates or folinic acid (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1990 |
Modulation of fluoropyrimidines by pretreatment with antifolates or folinic acid (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1990 |
Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump.
Topics: Ambulatory Care; Circadian Rhythm; Costs and Cost Analysis; Floxuridine; Home Care Services; Humans; | 1990 |
Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump.
Topics: Ambulatory Care; Circadian Rhythm; Costs and Cost Analysis; Floxuridine; Home Care Services; Humans; | 1990 |
Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine.
Topics: Animals; Brain Chemistry; Cisplatin; Endocrine System Diseases; Female; Floxuridine; Hepatic Artery; | 1990 |
Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine.
Topics: Animals; Brain Chemistry; Cisplatin; Endocrine System Diseases; Female; Floxuridine; Hepatic Artery; | 1990 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheterization, Central V | 1989 |
Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheterization, Central V | 1989 |
Phase I study of oral doxifluridine using two schedules.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug Tolerance; F | 1989 |
Phase I study of oral doxifluridine using two schedules.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug Tolerance; F | 1989 |
Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.
Topics: Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (NADP | 1989 |
Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.
Topics: Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (NADP | 1989 |
[Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Colonic Neoplasms; Drug Administ | 1985 |
[Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Colonic Neoplasms; Drug Administ | 1985 |
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration | 1985 |
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration | 1985 |
[Phase II study of 5'-DFUR (5'-deoxy-5-fluorouridine) by the Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla | 1985 |
[Phase II study of 5'-DFUR (5'-deoxy-5-fluorouridine) by the Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla | 1985 |
Upper gastrointestinal endoscopy for diagnosis of complications of regional hepatic chemotherapy.
Topics: Adult; Aged; Endoscopy; Female; Floxuridine; Gastrointestinal Diseases; Hepatic Artery; Humans; Infu | 1986 |
Upper gastrointestinal endoscopy for diagnosis of complications of regional hepatic chemotherapy.
Topics: Adult; Aged; Endoscopy; Female; Floxuridine; Gastrointestinal Diseases; Hepatic Artery; Humans; Infu | 1986 |
DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.
Topics: Aphidicolin; Cell Survival; Centrifugation, Density Gradient; Diterpenes; DNA, Neoplasm; Floxuridine | 1986 |
DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.
Topics: Aphidicolin; Cell Survival; Centrifugation, Density Gradient; Diterpenes; DNA, Neoplasm; Floxuridine | 1986 |
Phase II clinical evaluation of doxifluridine.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col | 1986 |
Phase II clinical evaluation of doxifluridine.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col | 1986 |
Enhancement of the effects of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Floxuridine; Fluoro | 1986 |
Enhancement of the effects of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Floxuridine; Fluoro | 1986 |
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Leukemia L | 1987 |
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Leukemia L | 1987 |
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans; | 1987 |
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans; | 1987 |
Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; DNA; Female; Floxuridine; Granulocytes; | 1988 |
Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; DNA; Female; Floxuridine; Granulocytes; | 1988 |
[Recent advances and trends in cancer chemotherapy using nucleoside analogs].
Topics: Animals; Cell Transformation, Neoplastic; Cytarabine; Floxuridine; Humans; Neoplasms; Nucleosides; S | 1988 |
[Recent advances and trends in cancer chemotherapy using nucleoside analogs].
Topics: Animals; Cell Transformation, Neoplastic; Cytarabine; Floxuridine; Humans; Neoplasms; Nucleosides; S | 1988 |
Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Floxuridine; Humans; Inf | 1988 |
Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Floxuridine; Humans; Inf | 1988 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
[Treatment of inoperable tumors by continuous and prolonged arterial perfusion of an antimitotic association].
Topics: Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Floxuridine; Fluor | 1969 |
[Treatment of inoperable tumors by continuous and prolonged arterial perfusion of an antimitotic association].
Topics: Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Floxuridine; Fluor | 1969 |
Cytochemical evaluation of metabolic inhibitors in cell culture.
Topics: Animals; Cell Division; Chloramphenicol; Culture Techniques; Dactinomycin; DNA; Floxuridine; Fluorou | 1965 |
Cytochemical evaluation of metabolic inhibitors in cell culture.
Topics: Animals; Cell Division; Chloramphenicol; Culture Techniques; Dactinomycin; DNA; Floxuridine; Fluorou | 1965 |
Effect of fluoropyrimidines on delayed cutaneous hypersensitivity.
Topics: Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Neoplasms; Pyrimidines; Skin Tests | 1965 |
Effect of fluoropyrimidines on delayed cutaneous hypersensitivity.
Topics: Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Neoplasms; Pyrimidines; Skin Tests | 1965 |
Clinical studies with systemic administration of antimetabolites of pyrimidine nucleosides in viral infections.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antimetabolites; Cytarabine; Female; Floxuridine; Gangrene; He | 1965 |
Clinical studies with systemic administration of antimetabolites of pyrimidine nucleosides in viral infections.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antimetabolites; Cytarabine; Female; Floxuridine; Gangrene; He | 1965 |
3',5'-Diesters of 5-fluoro-2'-deoxyuridine and thymidine: hydrolysis by esterases in human, mouse, and insect tissue.
Topics: Animals; Esterases; Female; Floxuridine; Humans; Injections, Intraperitoneal; Insecta; Mice; Neoplas | 1966 |
3',5'-Diesters of 5-fluoro-2'-deoxyuridine and thymidine: hydrolysis by esterases in human, mouse, and insect tissue.
Topics: Animals; Esterases; Female; Floxuridine; Humans; Injections, Intraperitoneal; Insecta; Mice; Neoplas | 1966 |
Six-hour intravenous infusions of 2'-deoxy-5-fluorouridine (NSC-27640): toxic effects and response rate.
Topics: Floxuridine; Humans; Injections, Intravenous; Neoplasms | 1967 |
Six-hour intravenous infusions of 2'-deoxy-5-fluorouridine (NSC-27640): toxic effects and response rate.
Topics: Floxuridine; Humans; Injections, Intravenous; Neoplasms | 1967 |
Further clinical evaluation of 2'-deoxy-5-fluorouridine (NSC-27640).
Topics: Female; Floxuridine; Humans; Male; Neoplasms | 1967 |
Further clinical evaluation of 2'-deoxy-5-fluorouridine (NSC-27640).
Topics: Female; Floxuridine; Humans; Male; Neoplasms | 1967 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Effects of elevated temperatures and drugs on the viability of L1210 leukemia cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Culture Media; Culture Techniques; Dactinomycin; Female; | 1970 |
Effects of elevated temperatures and drugs on the viability of L1210 leukemia cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Culture Media; Culture Techniques; Dactinomycin; Female; | 1970 |
5-Fluorouracil and derivatives in cancer chemotherapy. II. Possible in vivo formation and stabilization of 5-fluoro-2'-deoxyuridine.
Topics: Biopharmaceutics; Biotransformation; Chromatography, Thin Layer; Deoxyuridine; Dialysis; Drug Stabil | 1972 |
5-Fluorouracil and derivatives in cancer chemotherapy. II. Possible in vivo formation and stabilization of 5-fluoro-2'-deoxyuridine.
Topics: Biopharmaceutics; Biotransformation; Chromatography, Thin Layer; Deoxyuridine; Dialysis; Drug Stabil | 1972 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |
Evaluation of a cell-mediated cytotoxicity assay utilizing 125 iododeoxyuridine-labeled tissue-culture target cells.
Topics: Adult; AKR murine leukemia virus; Animals; Antigens, Neoplasm; Breast Neoplasms; Cell Line; Cells, C | 1973 |
Evaluation of a cell-mediated cytotoxicity assay utilizing 125 iododeoxyuridine-labeled tissue-culture target cells.
Topics: Adult; AKR murine leukemia virus; Animals; Antigens, Neoplasm; Breast Neoplasms; Cell Line; Cells, C | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Anisonucleolinosis in mammalian cell cultures.
Topics: Animals; Canavanine; Cell Nucleolus; Colchicine; Culture Techniques; Dactinomycin; Floxuridine; HeLa | 1966 |
Anisonucleolinosis in mammalian cell cultures.
Topics: Animals; Canavanine; Cell Nucleolus; Colchicine; Culture Techniques; Dactinomycin; Floxuridine; HeLa | 1966 |